Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Does the media favor CLDX or ALKS?

In the previous week, Alkermes had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 16 mentions for Alkermes and 6 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.56 beat Celldex Therapeutics' score of 0.09 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, CLDX or ALKS?

Celldex Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Do analysts rate CLDX or ALKS?

Celldex Therapeutics currently has a consensus price target of $51.75, suggesting a potential upside of 115.45%. Alkermes has a consensus price target of $41.08, suggesting a potential upside of 42.40%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Alkermes	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Which has stronger valuation and earnings, CLDX or ALKS?

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.02M	227.23	-$157.86M	-$3.01	-7.98
Alkermes	$1.56B	3.06	$367.07M	$2.08	13.87

Is CLDX or ALKS more profitable?

Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-3,446.88%	-27.61%	-26.20%
Alkermes	23.15%	24.86%	17.14%

Do insiders & institutionals believe in CLDX or ALKS?

95.2% of Alkermes shares are owned by institutional investors. 4.4% of Celldex Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alkermes beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks.